Market Cap (In USD)
8.5 Million
Revenue (In USD)
-
Net Income (In USD)
-535 Thousand
Avg. Volume
13.14 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.071-5.505
- PE
- -
- EPS
- -
- Beta Value
- 2.118
- ISIN
- US20678X1063
- CUSIP
- 20678X106
- CIK
- 1896212
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. David Joszef Tapolczay
- Employee Count
- -
- Website
- https://www.conduitpharma.com
- Ipo Date
- 2022-03-28
- Details
- Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
More Stocks
-
0JUJFormula One Group
0JUJ
-
LBTYBLiberty Global plc
LBTYB
-
SMTKSmartKem, Inc.
SMTK
-
PEXNY
-
DCMNVLDCM Nouvelle Limited
DCMNVL
-
SPZ
-
8158Soda Nikka Co., Ltd.
8158
-
DSX